Claims:

1. A method to treat or ameliorate neurological disorders comprising intrathecal injection of an effective amount of a double-stranded (ds) RNA into a subject in need, wherein said dsRNA inhibits the expression of a target gene.

2. A method according to claim 1 wherein said neurological disorder is selected from the group consisting of Alzheimer, Parkinson, multiple sclerosis, schizophrenia, epilepsy, depression and pain.

3. A method according to claim 1 or 2 wherein said neurological disorder is chronic neuropathic pain.

4. A method according to claim 1, 2 or 3 wherein said chronic pain is selected from the group consisting of cancer pain, osteoarthritis pain, allodynia and hyperalgesia.

5. A method according to any of the preceding claims wherein said target gene is selected from the group consisting of purine receptors P1 or P2, Galanin R1 receptor, IL-24, IL-20Ralpha, IL-20Rbeta, Mob-5 or MMP7.

6. The method according to any of the preceding claims wherein said target gene is P_2X_3 or P_2X_2 or Mob-5.

7. A method as in any of the preceding claims wherein the subject in need is a human.

8. A method as in any of claims 1-6 wherein the subject in need is a rat.

9. A method according to any of the preceding claims wherein at least 200µg of dsRNA are intrathecally injected.

10. A method according to any of the preceding claims wherein the dsRNA comprises a double-stranded region of 15 to 25 nt.

11. A method according to any of the preceding claims wherein the dsRNA comprises a 3'

overhang on the antisense or the sense strand, or both strands, of at least one nucleotide.

12. A method according to claim 10 wherein the overhang contains at least one modified nucleotide.

13. A method according to claim 11 wherein the overhang comprises at least one 2'-MOE modified nucleotide.

14. A method according to claim 10 wherein the overhang comprises 4 Uracils.

15. A method according to according any of the preceding claims wherein the dsRNA comprises at least one phosphorothioate linkage.

16. A pharmaceutical composition comprising an effective amount of a double stranded RNA inhibiting the expression of P_2X_3 or P_2X_2 in an amount effective to treat chronic pain in a subject in need.

17. A pharmaceutical composition comprising an effective amount of at least one double stranded RNA , said double stranded RNA comprising a strand of the sequence selected from the group consisting of SEQ ID Nos: 7, 9, 11, 13, 15, 17 and 22.

18. Use of a double stranded RNA for the preparation of a medicament for the treatment of chronic pain.

19. The use of claim 18 wherein the double stranded RNA inhibits purine receptors P1 or P2 or Galanin R1 receptor or IL-24 or IL-20Ralpha or IL-20Rbeta, Mob-5 or MMP7 or P_2X_3 or P_2X_2.

20. The use of claim 18 or 19 wherein said chronic pain is cancer pain or osteoarthritis pain or allodynia or hyperalgesia.